Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Down 5.6% in August

Dyadic International, Inc. (NASDAQ:DYAI) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 142,400 shares, a decline of 5.6% from the August 15th total of 150,900 shares. Based on an average daily trading volume, of 50,400 shares, the days-to-cover ratio is presently 2.8 days. Approximately 0.7% of the company’s shares are short sold.

Institutional Investors Weigh In On Dyadic International

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. grew its position in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 847,301 shares of the biotechnology company’s stock after acquiring an additional 21,000 shares during the quarter. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 27.95% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Dyadic International in a research note on Monday, July 8th.

Dyadic International Price Performance

Shares of DYAI opened at $1.19 on Friday. Dyadic International has a 52-week low of $1.13 and a 52-week high of $2.67. The company has a debt-to-equity ratio of 1.72, a quick ratio of 5.39 and a current ratio of 5.39. The business’s 50 day moving average price is $1.35 and its two-hundred day moving average price is $1.56. The firm has a market cap of $34.79 million, a PE ratio of -4.25 and a beta of 0.74.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The business had revenue of $0.39 million during the quarter, compared to analyst estimates of $1.00 million. Dyadic International had a negative net margin of 428.86% and a negative return on equity of 145.95%. During the same period last year, the firm posted ($0.07) earnings per share. On average, equities analysts anticipate that Dyadic International will post -0.26 EPS for the current year.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.